D-1370-2020 Class II Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-1370-2020 was initiated by Aurobindo Pharma USA Inc. on Jun 12, 2020 and is designated Class II. Reason for recall: Presence of foreign tablet: Consumer complaint of Clozapine Tablets 50mg being present in 500 count bottles of Clozapine Tablets USP 100mg. The recall status is terminated (terminated Dec 21, 2022). Affected quantity: 1440 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 1, 2020
Initiation Date
Jun 12, 2020
Termination Date
Dec 21, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1440 bottles

Product description

Clozapine Tablets USP tablet, 100mg, 500-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520, Made in India, NDC 65862-846-05

Reason for recall

Presence of foreign tablet: Consumer complaint of Clozapine Tablets 50mg being present in 500 count bottles of Clozapine Tablets USP 100mg.

Distribution pattern

U.S.A. Nationwide

Code information

Lot #: CZSC20003-A, Exp 1/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1370-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1370-2020. Report a data issue: hello@regdatalab.com.